The Endpoints Slack interview: Roivant CEO Matt Gline on playing moneyball in pharma, Vivek and politics, and the $7B Roche deal
As the ink dries on one of biotech’s biggest deals of 2023, Roivant Sciences CEO Matthew Gline popped in the secret Endpoints News Slack channel to discuss the latest with the wheeling-and-dealing biotech.
The 39-year-old ex-Goldman Sachs banker shared his thoughts on the $7.1 billion deal with Roche, playing pharma “moneyball,” and lessons learned working at Lehman Brothers during its final days. There’s also, of course, Vivek Ramaswamy, Roivant’s charismatic founder-turned-presidential-candidate who Gline succeeded.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.